Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spain pushes for higher colonoscopy testing rates:

This article was originally published in Clinica

Executive Summary

Prompter access to testing for colorectal cancer and higher survival rates are the ultimate aim of a Spanish public awareness booklet, published to mark the culmination of European colorectal cancer month. Among the topics featured in the Roche-sponsored guide are the early signs of disease and the importance of a prompt assessment using colonoscopy. Spain records annually some 22,000 new cases, of which 20% are at a metastatic stage, according to Europacolon Espana, the country's leading awareness and lobby group in this area. Greater public awareness should have a significant impact, it believes, on reducing this proportion of late diagnoses. Three-quarters of all cases appear in the 60-80 year age group and 90% of cases are aged over 50 (see Clinica No 1300, page 8).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel